Fulcrum Therapeutics
FULC | NASDAQ
$3.71
-$0.06 (-1.59%)
At close: Nov 16, 2026, 4:00 PM ET
$3.72
+$0.01 (+0.27%)
After-hours:
Nov 16, 2026, 5:58 PM ET
-1.59%
(1D)No price chart data available for 1D timeframe.
Rating
24.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #941/1021 (Top 92%)
Key Statistics
Market Data
Market Cap $283.38M
1D Range
3.70 3.78
52W Range
3.14 14.60
Valuation (TTM)
PE -3.57
PB 0.94
EV/EBITDA 0.24
Valuation (NTM)
Forward PE N/A
Forward PEG 0.07
Price Target $4.00
Cash Flow
FCF Yield -23.0%
SBC Adj. FCF Yield -27.4%
SBC Impact -18.9%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -150.0% |
-12.8%
Dil EPS 3Y | 5Y -43.3% |
25.9%
FCF 3Y | 5Y -63.1% |
15.5%
Returns
ROA -24.6%
ROE -23.6%
ROIC -24.7%
Financial Health
Net Cash
$306.55M
Current Ratio 36.19
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with...
Sector Healthcare
Industry Biotechnology
Employees 9
IPO Date Jul 18, 2019
Website www.fulcrumtx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
9
Consensus
Hold
Price Target
$4.00
Upside
+7.82%
Buy (1)
Hold (5)
Sell (3)
Add to Watchlist
Select watchlists to add or remove FULC